Rick Doblin - MDMA for PTSD in the US, Europe and Around the World

MDMA for PTSD is undergoing a global push for regulatory approval, driven by MAPS and their ongoing phase 3 clinical research. Regulatory agencies have largely cleared the path, acknowledging the efficacy of MDMA assisted therapy. The focus now shifts toward standardized therapist training and navigating the challenges of double blind study designs. A critical obstacle involves proving therapeutic superiority over an inactive placebo, leading researchers to compare MDMA against various low dose controls to maintain scientific rigor. Looking ahead, MAPS aims to scale its impact through models of expanded access and compassionate use. By establishing specialized clinics and training a robust workforce, the organization seeks to mainstream this therapeutic approach while also considering applications for other conditions and demographic groups, including pediatric populations.